Ferrum Crescent Ltd (LON:FCR) Investors: Beaufort Securities Reconfirms Speculative Buy Rating; Sphera Funds Management LTD Raised Biogen (BIIB) Stake

January 12, 2018 - By David Stenberg

The stock rating of Ferrum Crescent Ltd (LON:FCR) was reaffirmed by stock research analysts at Beaufort Securities. This was revealed to investors in an analyst report on Friday morning.

Sphera Funds Management Ltd increased Biogen Inc (BIIB) stake by 16.67% reported in 2017Q3 SEC filing. Sphera Funds Management Ltd acquired 15,000 shares as Biogen Inc (BIIB)’s stock declined 13.45%. The Sphera Funds Management Ltd holds 105,000 shares with $32.88 million value, up from 90,000 last quarter. Biogen Inc now has $70.44 billion valuation. The stock decreased 1.08% or $3.65 during the last trading session, reaching $333.07. About 1.00 million shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 12, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Among 2 analysts covering Ferrum Crescent Ltd (LON:FCR), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Ferrum Crescent Ltd had 26 analyst reports since July 23, 2015 according to SRatingsIntel. On Thursday, December 17 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. On Wednesday, April 6 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. The stock has “Speculative Buy” rating by Beaufort Securities on Thursday, November 10. Beaufort Securities maintained the shares of FCR in report on Monday, February 1 with “Speculative Buy” rating. The firm has “Speculative Buy” rating given on Thursday, July 23 by Beaufort Securities. Beaufort Securities maintained Ferrum Crescent Limited (LON:FCR) on Wednesday, June 21 with “Speculative Buy” rating. The firm has “Speculative Buy” rating given on Monday, November 2 by Beaufort Securities. The firm has “Speculative Buy” rating given on Friday, December 2 by Beaufort Securities. The firm has “Speculative Buy” rating by Beaufort Securities given on Friday, January 15. The firm has “Speculative Buy” rating given on Friday, April 1 by Beaufort Securities.

The stock decreased 5.12% or GBX 0.006 during the last trading session, reaching GBX 0.102. About 70.54M shares traded or 73.68% up from the average. Ferrum Crescent Limited (LON:FCR) has 0.00% since January 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Ferrum Crescent Limited engages in the exploration of mineral properties. The company has market cap of 4.91 million GBP. It holds a 100% interest in Toral and Lago lead-zinc exploration projects located respectively in the provinces of Le??n and Galicia in Spain. It currently has negative earnings.

Sphera Funds Management Ltd decreased Syndax Pharmaceuticals Inc stake by 47,838 shares to 248,472 valued at $2.91 million in 2017Q3. It also reduced Immunomedics Inc (NASDAQ:IMMU) stake by 100,000 shares and now owns 450,000 shares. Teva Pharmaceutical Fin Llc was reduced too.

Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Biogen Idec Inc. has $450 highest and $268 lowest target. $352.97’s average target is 5.97% above currents $333.07 stock price. Biogen Idec Inc. had 95 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, February 25 by Citigroup. The firm earned “Hold” rating on Thursday, September 28 by Robert W. Baird. As per Monday, November 7, the company rating was upgraded by PiperJaffray. The firm has “Hold” rating by BMO Capital Markets given on Thursday, June 1. The stock has “Hold” rating by Cantor Fitzgerald on Tuesday, October 24. On Tuesday, August 25 the stock rating was maintained by Cowen & Co with “Buy”. RBC Capital Markets maintained the shares of BIIB in report on Monday, July 27 with “Outperform” rating. Raymond James initiated the shares of BIIB in report on Tuesday, September 1 with “Strong-Buy” rating. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. The rating was maintained by BMO Capital Markets on Wednesday, July 26 with “Market Perform”.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.25, from 0.88 in 2017Q2. It increased, as 59 investors sold BIIB shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported. 1,574 were accumulated by Garde Capital. Amer Group Inc holds 0.1% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 89,637 shares. Mitsubishi Ufj Tru Banking invested in 445,465 shares or 0.26% of the stock. 21 were accumulated by Contravisory Inv Mgmt. Gemmer Asset Ltd Com holds 0.02% or 189 shares. Jump Trading Ltd Liability Company holds 81 shares. Twin Focus Cap Prns Lc has invested 0.14% in Biogen Inc. (NASDAQ:BIIB). Eaton Vance Management accumulated 448,373 shares. Assetmark stated it has 389 shares. Los Angeles Capital Management And Equity Research invested 0.28% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Eastern National Bank reported 0.04% stake. Bessemer Grp Incorporated accumulated 1,058 shares. Penobscot invested 0.08% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Great Lakes Lc invested in 2,827 shares or 0.02% of the stock. Roundview Capital Limited Liability Company reported 0.1% stake.

Since January 9, 2018, it had 0 insider purchases, and 1 sale for $1.92 million activity. $1.92M worth of Biogen Inc. (NASDAQ:BIIB) was sold by PANGIA ROBERT W on Tuesday, January 9.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg







Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: